Indivior Pharmaceuticals, Inc. INDV SUBLOCADE — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Indivior Pharmaceuticals, Inc. 's sublocade — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Indivior Pharmaceuticals, Inc. 's SUBLOCADE — net revenue?
- Indivior Pharmaceuticals, Inc. (INDV) reported SUBLOCADE — net revenue of $232M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc. 's SUBLOCADE — net revenue changed year-over-year?
- Indivior Pharmaceuticals, Inc. 's SUBLOCADE — net revenue increased by 31.8% year-over-year, from $176M to $232M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc. 's SUBLOCADE — net revenue?
- Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc. 's SUBLOCADE — net revenue has grown at a 28.0% compound annual growth rate (CAGR), from $408M to $856M.
- What does SUBLOCADE — net revenue mean?
- This metric represents the total revenue generated from the sale of a specific pharmaceutical product after accounting for returns, discounts, and rebates. It serves as a primary indicator of the product's market adoption, commercial success, and contribution to the company's overall top-line growth. Monitoring this figure helps investors assess the product's lifecycle stage and its ability to capture market share within its therapeutic category.